The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
REGULATORY
Japan Approves Symbicort Generics, Asthma Drug Stalwart Could Face Competition in June
The Ministry of Health, Labor and Welfare (MHLW) on February 15 gave the green light to a raft of new generic drugs ahead of the next generic reimbursement listing in June, including lower-cost copies of AstraZeneca’s asthma treatment Symbicort (budesonide…
To read the full story
Related Article
- 15% Share Eyed for Jointly Developed Symbicort Generics, Toa Set to Push Uptake with Support App
December 25, 2019
- 6 Drugs Face Generic Entries, 2 Firms to Roll Out Symbicort Copies: December Listing
December 12, 2019
- Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
June 13, 2019
- Toa Confident in Ensuring Stable Supply of Symbicort Generic with Expertise in Dry Powder Inhaler Manufacturing
March 8, 2019
- Nihon Generic Taking Pass on June Listing of Symbicort Copies; 2 Partners Mum
February 27, 2019
- Asahi Kasei Pharma Sets Up New Firm for Teribone Authorized Generic
February 18, 2019
- Toa, Nipro, Nihon Generic Codeveloped Symbicort Copies, Launch Timing Unclear
February 18, 2019
REGULATORY
- LDP Project Team Eyes Coverage Discussions for Drug Use in Pre-Symptomatic Stage
May 20, 2025
- New Stelara Biosimilars Earn May Listing, Eylea Follow-On Takes Pass Again
May 20, 2025
- Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
- Ex-Lawmakers’ Club Proposes CEA Overhaul, GDP-Linked Drug Spending
May 16, 2025
- Ex-PM Kishida Stresses Need to Bolster Innovation in Japan: Tokyo Speech
May 16, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…